Concomitant targeting of tumor cells and induction of T cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

被引：0
|
作者：
Wang, Qingfei [1 ]
Li, Shau-Hsuan [1 ]
Wang, Hai [1 ]
Xiao, Yi [1 ]
Sahin, Ozgur [1 ]
Brady, Samuel W. [1 ]
Li, Ping [1 ]
Jaffee, Elizabeth M. [2 ,3 ]
Hortobagyi, Gabriel N. [1 ]
Yu, Dihua [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Sidney Kimmel Canc Ctr Johns Hopkins, Baltimore, MD USA
[3] Viragh Pancreat Canc Ctr, Baltimore, MD USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB215
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
    Barok, Mark
    Tanner, Minna
    Koninki, Katri
    Isola, Jorma
    BREAST CANCER RESEARCH, 2011, 13 (02):
  • [22] Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies
    Szoor, Arpad
    Toth, Gabor
    Zsebik, Barbara
    Szabo, Viktoria
    Eshhar, Zelig
    Abken, Hinrich
    Vereb, Gyorgy
    CANCER LETTERS, 2020, 484 : 1 - 8
  • [23] Phase I/II trail of everoiimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer.
    Morrow, P. H.
    Wulf, G. M.
    Booser, D. J.
    Moore, J. A.
    Flores, P. R.
    Krop, I. E.
    Winer, E. P.
    Hortobagyi, G. N.
    Yu, D.
    Esteva, F. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
    Mark Barok
    Minna Tanner
    Katri Köninki
    Jorma Isola
    Breast Cancer Research, 13
  • [25] HER2-specific T lymphocytes kill both trastuzumab-resistant and trastuzumab-sensitive breast cell lines in vitro
    Lin, Xiao-lin
    Wang, Xiao-li
    Ma, Bo
    Jia, Jun
    Yan, Ying
    Di, Li-jun
    Yuan, Yan-hua
    Wan, Feng-ling
    Lu, Yuan-li
    Liang, Xu
    Shen, Tao
    Ren, Jun
    CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (02) : 143 - 150
  • [26] Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer
    Dokmanovic, Milos
    Hirsch, Dianne S.
    Shen, Yi
    Wu, Wen Jin
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (06) : 1557 - 1569
  • [27] Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells
    Gao, Yu
    Shelling, Andrew N.
    Nolan, Emma
    Porter, David
    Leung, Euphemia
    Wu, Zimei
    JOURNAL OF LIPOSOME RESEARCH, 2024, 34 (03) : 489 - 506
  • [28] t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells
    Lenz, Gal
    Hamilton, Angelica
    Geng, Shuhui
    Hong, Teresa
    Kalkum, Markus
    Momand, Jamil
    Kane, Susan E.
    Huss, Janice M.
    CLINICAL CANCER RESEARCH, 2018, 24 (05) : 1216 - 1226
  • [29] HER2-Specific T Lymphocytes Kill both Trastuzumab-Resistant and Trastuzumab-Sensitive Breast Cell Lines In Vitro
    Xiao‐lin Lin 1
    Chinese Journal of Cancer Research, 2012, 24 (02) : 143 - 150
  • [30] Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1
    Rennstam, Karin
    Jonsson, Goran
    Tanner, Minna
    Bendahl, Par-Ola
    Staaf, Johan
    Kapanen, Anita I.
    Karhu, Ritva
    Baldetorp, Bo
    Borg, Ake
    Isola, Jorma
    CANCER GENETICS AND CYTOGENETICS, 2007, 172 (02) : 95 - 106
12345